Therapeutic | Garetosmab |
Target | INHBA |
Heavy Chain | QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS |
Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | Regeneron Pharmaceuticals |
Conditions Approved | na |
Conditions Active | Fibrodysplasia ossificans progressiva, Musculoskeletal disorders |
Conditions Discontinued | na |
Notes |